ABBV-706 + ATEZOLIZUMAB + Alveltamig for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Oct 2026: Trial registered, NCT07895043

The trials

NCT07895043: A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer

State
Not started
Phase
Phase 2
People
80 planned
Started
20 Nov 2026
Primary completion
Dec 2031
Arms
ABBV-706 Dose A + Alveltamig + Atezolizumab, ABBV-706 Dose B + Alveltamig + Atezolizumab
Results
None posted
  1. 26 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.